key: cord-1045384-nad6lmat
authors: Fleiss, Noa; Tarun, Samiksha; Polin, Richard A.
title: Infection Prevention for Extremely Low Birth Weight Infants in the NICU
date: 2022-04-13
journal: Semin Fetal Neonatal Med
DOI: 10.1016/j.siny.2022.101345
sha: bc83cf824dfe453d99a174a7777ca7a6b236114c
doc_id: 1045384
cord_uid: nad6lmat

Extremely preterm infants are particularly vulnerable to systemic infections secondary to their immature immune defenses, prolonged hospitalizations, delays in enteral feeding, early antibiotic exposure, and need for life-sustaining invasive interventions. There have been several evidence-based practices for infection prevention in this population, such as human milk feedings, utilization of “bundle checklists” and decolonization of pathogenic organisms. Other practices, such as the use of probiotics, human milk-derived fortifiers, and antifungal prophylaxis are more controversial and require further investigation regarding the risks and benefits of such interventions. This chapter examines the susceptibility of the preterm newborn infant to invasive infections and describes several strategies for infection prevention, along with the associated limitations of such practices. It also addresses the various gaps in our understanding of preventing infections in this population, and the need for additional large multi-center randomized controlled trials. Additionally, the role of the SARs-CoV-2 global pandemic and associated strategies for infection prevention in the NICU are discussed.

Necrotizing enterocolitis (NEC) is a multifactorial disease in which the susceptibility of the preterm intestine, immunodeficiencies associated with preterm delivery, nutritional practices and the intestinal microbiome play critical roles. 17 The gastrointestinal microbiota is mostly composed of bacteria from two major phyla, Bacteroidetes (gram negative bacteria) and

Firmicutes (Lactobacillus and other gram-positive bacteria). Other important phyla, especially with regard to NEC development include Proteobacteria (pathogenic gram-negative bacteria)

and Actinobacteria (Bifidobacterium and other gram-positive bacteria). Until fairly recently, culture-based methods were used to identify and define the microorganisms colonizing various body sites. Recent advances in molecular techniques (16S RNA sequencing and shotgun metagenomics) have allowed investigators to characterize the microbiome of the preterm infant with much greater precision and examine its role in the pathogenesis of diseases such as NEC. 18 Use of drugs which suppress gastric acidity has been shown to alter the microbiome. 19 Both proton pump inhibitors and H2-blockers have been correlated with increased abundance of colonization with Proteobacteria, Actinobacteria and Bacteroidetes. Antibiotics for early-onset sepsis decrease the numbers of Firmicutes and increase the abundance of Proteobacteria. 20 Intrapartum antibiotic prophylaxis has been shown to alter the microbiome for months postnatally, by increasing Proteobacteria and decreasing Actinobacteria, Bifidobacterium and Bacteroides. 21 Furthermore, prolonged treatment with antibiotics for early-onset sepsis has been associated with an increased risk of necrotizing enterocolitis and late onset sepsis. 22, 23 In term infants, the abundance and diversity of bacteria is decreased at birth. 24 In comparison, bacterial diversity is further decreased in infants delivered preterm and is characterized by high numbers of Firmicutes and Proteobacteria (e.g., Enterobacteriaceae) and low levels of Bifidobacterium.

This abnormal pattern of colonization may alter the structural barrier of the intestine resulting in increased permeability and bacterial translocation, ultimately leading to NEC (figure1). No single bacterium has been causally linked to the development of NEC. However, NEC has been associated with a "bloom" in Proteobacteria, particularly Enterobacteriaceae, and a decrease in Firmicutes and Bacteroidetes. 26 This process termed dysbiosis is believed to precede the development of NEC. Enterobacteriaceae interact with toll like receptor-4, which is known to regulate the balance between healing and repair in the intestine 27 and is upregulated in infants with NEC. 28 However, it is unclear if the "bloom" of gram-negative bacteria actually causes NEC or that NEC results from the concurrent decrease of commensal bacteria (e.g., Firmicutes), which might be cytoprotective.

Probiotics are live microbial supplements which provide benefit to the host beyond that of nutrition. Breast milk contains a variety of probiotics, but unfortunately is not always available to the preterm infant. Donor breast milk provides suboptimal nutrition unless fortified and does not contain viable bacteria once pasteurized. Probiotics have been shown to increase mucin and defensin production, decrease adherence of pathogens, enhance tight junctions, increase the J o u r n a l P r e -p r o o f 6 number of IgA producing cells, kill pathogenic bacteria and dampen the inflammatory response. 29 .

Dr. Angela Hoyos in Bogota Colombia was the first clinician to use probiotics in a NICU setting. 30 She treated every baby with Infloran containing Bifidobacteria and Lactobacillus acidophilus, which resulted in a marked decline in NEC and NEC related deaths. Probiotics have been administered to thousands of newborn infants in randomized clinical trials and observational studies. The encouraging news is that the use of probiotics is relatively safe, except for the rare infant who develops sepsis with the probiotic organism or a contaminant. However, there are several controversies surrounding probiotic use. For example, the manufacturing processes for probiotics are not tightly regulated in the United States. The Food and Agriculture Organization/World Health Organization has issued recommendations on information that J o u r n a l P r e -p r o o f should be present on the product label, including; genus, species, strain designation, minimal viable number of each probiotic strain at the end of shelf life, the recommended effective dose of the probiotic, health claims, storage conditions and corporate contact details. That information is not generally available for commercial probiotic products used in the United States. There have been a number of studies testing the purity and content of commercial probiotic supplements. On the positive side, Shehata and Newmaster tested 182 probiotic "dietary supplements" from the United States and Canada 31 and found that only 8% of samples were non-compliant with labelling. However, several studies found both contamination (with potential pathogens) and missing species in a high percentage of probiotic supplements. [32] [33] [34] [35] [36] [37] [38] [39] Other studies found that the number of viable counts were lower than indicated on the label. 33, 37, [39] [40] [41] It is important to note that most of the studies assessing viable bacterial counts were conducted on samples from different countries on a limited number of specimens. In Europe, probiotic containing foods and supplements are carefully regulated. Over 3,000 health claims for probiotics were rejected by the European commission except for better lactose digestion when used in yogurt cultures. In the United States, probiotics are considered dietary supplements and health claims are not regulated.

The phrase "buyer beware" is appropriate when using off-the-shelf dietary supplements in preterm infants. There is a great need for pharmaceutical grade probiotic supplements.

The population of infants < 28 week's gestation is most susceptible to NEC. However, the majority of randomized trials examining effectiveness of probiotics have not included large numbers of infants in this gestational age stratum. Meta-analyses have been problematic because it is difficult to compare studies using different probiotic species. For example, Underwood et al performed a dose escalation study comparing two microbial strains (B infantis and B. lactis).

Only B. infantis was able to colonize the gastrointestinal tract, B. lactis did not. Furthermore B.

lactis is unable to utilize breast milk oligosaccharides. 42 In addition, the quality of the metaanalyses differed considerably and as of 2020 only one was rated as high quality based on AMSTAR criteria. 43 In a recent systematic analysis from the Cochrane library 44 Sharif et al concluded that probiotics may reduce the incidence of NEC (conclusion rated as low certaintynumber needed to benefit = 33). The evidence was assessed as low certainty because of limitations in trial design and publication bias. This meta-analysis also concluded that probiotics probably reduced mortality and infection. However, sensitivity meta-analyses of 16 trials at low J o u r n a l P r e -p r o o f risk of bias showed that probiotics reduced NEC but had no effect on mortality or infection rates.

Importantly, there was no significant benefit of probiotics on the incidence of NEC in extremely low birth weight infants. These results should be cautiously interpreted as relatively few studies were included in these analyses and the authors warn that estimates might be imprecise. 44 In a strain specific meta-analysis by van den Akker et al. only a minority of single strains or combination of strains reduced mortality or morbidity in clinical trials. 45 Importantly, most randomized clinical trials have not confirmed the purity of the product used in each study.

Fungal sepsis has been reported from a NICU in which the commercial product contained the contaminating fungus. 46 Many manufacturers change the strains in the probiotic product without changing the label. Therefore, there is uncertainty what strain is actually being administered. Of the hundreds of probiotic trials, it is noteworthy that only two commercial probiotics studied in clinical trials have been shown to both increase colonization with the probiotic strain in the intestine and decrease colonization with Enterobacteriaceae. 47 Finally, most randomized trials have not considered cross contamination of the probiotic to the control group, which might benefit infants in the control group and dilute any potential benefit of probiotics.

Based on a careful review of all available evidence, the Committee on Fetus and Newborn of the American Academy of Pediatrics concluded that "Given the lack of FDA-regulated pharmaceutical grade products in the United States, conflicting data on safety and efficacy, and potential for harm in a highly vulnerable population, current evidence does not support the universal administration of probiotics to preterm infants, particularly those with birthweights < 1,000 grams." 48 Several large randomized clinical trials using pharmaceutical grade product are in progress.

Human milk contains a variety of antimicrobial factors and immunomodulating agents and has a unique microbiome that may serve as a source of commensal bacteria (Bifidobacterium and Lactobacillus). 49, 50 However, unpasteurized breast milk may contain a variety of species, some of which may be pathogenic for the neonate. In preterm infants, use of human milk is considered an evidenced based strategy to reduce the incidence of NEC. However, in mothers delivering very J o u r n a l P r e -p r o o f preterm infants, the supply of human milk may initially be inadequate and require supplementation (donor breast milk or formula), or calorically inadequate and require milk fortifiers (bovine or human). Observational studies of feeding infants with mother's own milk demonstrate a reduction in the incidence of NEC. Randomized clinical trials, by necessity, have only included donor breast milk that was supplemented with human-milk derived or bovinederived fortifiers. Donor breast milk is pasteurized which alters some of the immunological benefits, without significantly affecting the nutritional composition. Furthermore, donor breast milk is usually collected from women delivering infants at term, in whom the nutrient supply is very different from that found in milk from women delivering preterm infants. As with the systematic reviews of probiotics, the meta-analyses of human breast milk vs formula are very heterogeneous and include studies of infants fed an exclusively human diet vs. those receiving varying amounts of bovine fortified donor milk or formula. Furthermore, the meta-analyses include studies conducted over a number of years. However, a few generalizations are still possible.

• All meta-analyses demonstrated a reduction in the incidence of NEC with donor milk compared with preterm formula.

• There is no difference in all-cause mortality in infants fed formula vs. donor milk.

• There is no difference in tolerance of feedings with donor milk or formula.

• Formula fed infants exhibited significantly better weight gain and linear growth.

In the systematic review of Quigley et al, growth in head circumference was also faster with formula, but not when donor breast milk was fortified. 51 • No long-term differences in neurodevelopment or growth have been demonstrated • There is no evidence that breast milk decreases the risk of late onset sepsis.

Although controversial, there is no evidence that human milk-based fortifiers decrease the risk of NEC vs. fortifiers prepared from bovine sources. The recent meta-analysis of Grace et al, which concluded that human milk derived fortifiers resulted in a lower incidence of NEC included only two studies and is too small to make meaningful conclusions. 52 J o u r n a l P r e -p r o o f

LOS, or sepsis occurring after 72 hours of life, is a major contributor of neonatal morbidity and mortality, with an incidence of 1-2 per 1000 live born newborns and a high overall mortality rate. [53] [54] [55] Gram positive organisms, specifically Staphylococcus aureus, account for the majority of LOS infections. Coagulase negative Staphylococcus (CoNS) is often cited as a leading cause of LOS in the NICU. 53, 54, 56 However, based on more recent definitions of true bacteremia, as opposed to blood sample contamination with CoNS, the prevalence of CoNS LOS is likely less than previously reported. 57, 58 Gram negative bacteria, such as Escherichia coli, Enterobacter, and Klebsiella, as well as fungal species, primarily Candida albicans, are also responsible for LOS and have an overall higher mortality rate than gram positive infections. 53,54

Episodes of LOS are often viewed as preventable hospital acquired infections (HAI). Central line associated bloodstream infections (CLABSI) are the most common HAI in the NICU, due to sustained need for vascular access and a lengthy hospital stay. A peripherally inserted central catheter (PICC) is most commonly used in neonates and several evidence-based practices have been implemented for CLABSI prevention. [59] [60] [61] [62] Over the last decade, there has been a considerable shift in perception of CLABSI, from an unavoidable complication of a life-saving intervention to a preventable and reportable medical error that requires intervention. 61 The Institute for Healthcare Improvement (IHI) together with the Centers for Disease Control and Prevention (CDC) and other national scientific organizations have issued evidence-based guidelines that promote using central line bundles to improve CLABSI rates in the healthcare setting. 63, 64 Care bundles are an "all-or-nothing" approach of evidence-based practices, that when implemented simultaneously, improve outcomes. In the case of CLABSI prevention bundles, there are 5 key best practices that require full compliance: 

VLBW and ELBW neonates are at increased risk for invasive fungal disease, which is associated with increased morbidity mortality and neurodevelopmental impairments. 54, 86 The incidence of invasive fungal disease in these birth weight populations ranges widely with an average of 16% (range 4-43%). 87 The majority of cases are caused by Candida species, specifically Candida albicans and Candida parapsilosis, and typically cause late-onset sepsis. 54 However, a few cases occur through vertical transmission and may cause early-onset sepsis. Attempting to prevent invasive fungal disease in high-risk patients is imperative to avoid mortality and long-term sequelae.

Minimizing risk factors for fungal sepsis is an important way to minimize the risk of disease.

Modifiable risk factors include: prolonged exposure to empiric antibiotics, exposure to 3 rd generation cephalosporins and other broad-spectrum antibiotics, and use of foreign bodies (such as endotracheal tubes, central venous or arterial catheters and other hardware). [88] [89] Other risk factors for invasive fungal disease include positive pressure ventilation and intubation, gastrointestinal pathology, previous blood stream infection, parenteral nutrition and intravenous lipids. 89 In a matched case-control study, multivariate analyses showed that candidemia was associated with prolonged catheter use, which had an odds ratio of 1.06 per day of use (95% CI of 1.02-1.10) and with previous blood stream infection, with an odds ratio of 8.02 (95% CI of 2. 76 -23.30 ). 89 It is well established that reducing exposure to these risk factors is associated with a reduction in risk of systemic fungal disease. 88 J o u r n a l P r e -p r o o f

Antifungal prophylaxis is used to reduce the risk of invasive fungal disease; however, variations in this practice exist worldwide. Fluconazole seems to be emerging as the drug of choice for prophylaxis. It has a long half-life, is excreted renally, and has a good safety profile, although more studies in neonates are needed. 90 Side effects reported include transaminitis 91 have been used to reduce the incidence of fungal infections. Neither of these agents have been adequately studied in neonates. In a randomized control trial comparing prophylaxis with nystatin, fluconazole and placebo, the incidence of fungal infections was 4.3% in nystatin group, 3 .2% in fluconazole group and 16.5% in placebo group. 95 A 2015 Cochrane Review concluded that prophylactic systemic antifungal therapy may reduce the incidence of invasive fungal infection in very low birth weight infants, however, there was considerable heterogeneity in the reported studies. 96 It is re-assuring that of the studies done, there seems to be a lack of emergence of resistant fungal species for neonates who have received antifungal agents (IDSA) and there does not seem to be an emergence of inherently resistant fluconazole fungal species. 97 Continued surveillance and monitoring of the fungal ecology in NICUs where fluconazole or nystatin prophylaxis is adopted is warranted to exclude these unwanted shifts in sensitivity to these agents.

J o u r n a l P r e -p r o o f

The emergence of the severe acute respiratory syndrome coronavirus 2 (SARs-CoV-2) pandemic has dramatically changed the way we deliver healthcare globally. While SARs-CoV-2 has not had major clinical implications for preterm infants in the NICU, 98, 99 it has led to more rigid infection prevention strategies (i.e., visitor restrictions, hand hygiene, environmental disinfection, and donning of personal protective equipment). Maternal breastmilk has been more closely examined as a potential protective mechanism for infants of women who were previously infected with SARs-CoV-2 or immunized with the vaccine. Multiple studies have shown that maternal spike specific IgA targeting SARs-CoV-2 is found in breastmilk of mothers previously infected or vaccinated 100-102 without evidence of SARs-CoV-2 transmission. 103 Similarly, breastfed infants have been shown to have salivary IgA specific for SARs-CoV-2, which is important for stimulating the mucosal immune response. 102 While very premature infants are not capable of initiating breastfeeding until much later in their NICU stay, expressed maternal breastmilk has been encouraged and should be used whenever possible.

While risk factors for maternal to neonatal transmission of SARs-CoV-2 are not fully understood, several precautions and management strategies for mother-infant dyads have been proposed. In an observational cohort study of 120 neonates born to SARS-CoV-2 infected mothers, 68% completed follow up, and all tested negative for the virus at 5-7 days of life as well as 14 days of life. 104 The American Academy of Pediatrics recommends that all SARS-CoV-2 positive mothers and newborns room-in after delivery, per hospital standard practice, while taking precautions such as hand hygiene and use of surgical mask during breastfeeding and hands-on care. 105 While the preterm population is not rooming-in with an infected mother, the Academy of Pediatrics guidelines recommends cohorting the infant in a negative pressure room and having the medical staff take precautions (N95, eye protection, don gown and gloves) until the infant tests negative within the first 72 hours of age. Additionally, visitation restrictions are in place for a mother with SARs-CoV-2.

Given the emerging data that vaccine provides some protection to neonate due to transplacental transfer of SARs-CoV-2 antibodies after covid19 vaccination during pregnancy, it is important to understand the safety of covid19 vaccine administration and promote its use in pregnant and lactating women. Preliminary results for safety of mRNA covid19 vaccine in pregnant women

Innate immunity of the newborn: basic mechanisms and clinical correlates

Prenatal Immunity and Influences on Necrotizing Enterocolitis and Associated Neonatal Disorders

Concentrations of main serum opsonins in early infancy

Evidence-based skin care in preterm infants

Why are preterm newborns at increased risk of infection?

Skin barrier in the neonate

How colonization by microbiota in early life shapes the immune system

Oral administration of maternal vaginal microbes at birth to restore gut microbiome development in infants born by caesarean section: A pilot randomised placebocontrolled trial

The Microbiome and Metabolome of Preterm Infant Stool Are Personalized and Not Driven by Health Outcomes, Including Necrotizing Enterocolitis and Late-Onset Sepsis

Recent advances in understanding the neonatal microbiome. F1000Res 9

Factors associated with intrapartum transmission of group B Streptococcus

Patterned progression of bacterial populations in the premature infant gut

Maternal influences on fetal microbial colonization and immune development

Study provides evidence that 'vaginal seeding' of infants born by caesarean partially restores microbiota

Partial restoration of the microbiota of cesarean-born infants via vaginal microbial transfer

Vaginal seeding' after a caesarean section provides benefits to newborn children: AGAINST: Vaginal microbiome transfer -a medical procedure with clear risks and uncertain benefits

Necrotizing enterocolitis

Dynamics of the preterm gut microbiome in health and disease

Proton pump inhibitors alter the composition of the gut microbiota

High-throughput sequencing reveals the incomplete, short-term recovery of infant gut microbiota following parenteral antibiotic treatment with ampicillin and gentamicin

Impact of intrapartum antimicrobial prophylaxis upon the intestinal microbiota and the prevalence of antibiotic resistance genes in vaginally delivered full-term neonates

Modifiable Risk Factors in Necrotizing Enterocolitis

Risk Factors for Necrotizing Enterocolitis: A Prospective Multicenter Case-Control Study

The Microbiota of the Extremely Preterm Infant

Toll-Like Receptor-Mediated Intestinal Inflammatory Imbalance in the Pathogenesis of Necrotizing Enterocolitis

Intestinal dysbiosis in preterm infants preceding necrotizing enterocolitis: a systematic review and meta-analysis. Microbiome

Building an intestine--architectural contributions of commensal bacteria

Necrotizing enterocolitis: new insights into pathogenesis and mechanisms

Probiotic bacteria and intestinal epithelial barrier function

Reduced incidence of necrotizing enterocolitis associated with enteral administration of Lactobacillus acidophilus and Bifidobacterium infantis to neonates in an intensive care unit

Combined Targeted and Non-targeted PCR Based Methods Reveal High Levels of Compliance in Probiotic Products Sold as Dietary Supplements in United States and Canada

Identification of probiotic microorganisms in South African products using PCR-based DGGE analysis

Microbiological and genetic identification of some probiotics proposed for medical use in 2011

Culture-Independent Metagenomic Surveillance of Commercially Available Probiotics with High-Throughput Next-Generation Sequencing

Validating bifidobacterial species and subspecies identity in commercial probiotic products

Karunasagar, I. & Karunasagar, I. Composition and Laboratory Correlation of

Genotyping by PCR and High-Throughput Sequencing of Commercial Probiotic Products Reveals Composition Biases

Accuracy of species identity of commercial bacterial cultures intended for probiotic or nutritional use

National survey outcomes on commercial probiotic food supplements in Italy

Microbiological evaluation of commercial probiotic products available in the USA in 2009

Bacterial composition of commercial probiotic products as evaluated by PCR-DGGE analysis

A comparison of two probiotic strains of bifidobacteria in premature infants

Prevention of necrotizing enterocolitis with probiotics: a systematic review and meta-analysis

Probiotics to prevent necrotising enterocolitis in very preterm or very low birth weight infants

Probiotics for Preterm Infants: A Strain-Specific Systematic Review and Network Meta-analysis

Probiotics and necrotizing enterocolitis

Safety and efficacy of probiotic administration to preterm infants: ten common questions

Use of Probiotics in Preterm Infants

Repertoire of human breast and milk microbiota: a systematic review

Human Milk's Hidden Gift: Implications of the Milk Microbiome for Preterm Infants' Health

Formula versus donor breast milk for feeding preterm or low birth weight infants

Safety and efficacy of human milk-based fortifier in enterally fed preterm and/or low birthweight infants: a systematic review and meta-analysis

Early and late onset sepsis in very-low-birth-weight infants from a large group of neonatal intensive care units

Late-onset sepsis in very low birth weight neonates: the experience of the NICHD Neonatal Research Network

Early and Late Infections in Newborns: Where Do We Stand? A Review

Seventy-five years of neonatal sepsis at Yale: 1928-2003

Neonatal sepsis 2004-2013: the rise and fall of coagulase-negative staphylococci

Distinguishing true coagulase-negative Staphylococcus infections from contaminants in the neonatal intensive care unit

Central line-associated bloodstream infections in the NICU: Successes and controversies in the quest for zero

Peripheral intravenous cannulation: complication rates in the neonatal population: a multicenter observational study

Central line-associated bloodstream infections in neonatal intensive care: changing the mental model from inevitability to preventability

Guidelines for the prevention of intravascular catheter-related infections

The 100,000 lives campaign: setting a goal and a deadline for improving health care quality

Central line bundle implementation in US intensive care units and impact on bloodstream infections

A multicenter intervention to prevent catheter-associated bloodstream infections

Effectiveness of surveillance of central catheter-related bloodstream infection in an ICU in Korea

Reducing central line-associated bloodstream infections in North Carolina NICUs

Development of a statewide collaborative to decrease NICU central lineassociated bloodstream infections

A statewide quality improvement collaborative to reduce neonatal central line-associated blood stream infections

Neurodevelopmental and growth impairment among extremely low-birth-weight infants with neonatal infection

Healthcare-associated bloodstream infections in a neonatal intensive care unit over a 20-year period (1992-2011): trends in incidence, pathogens, and mortality

Late-onset sepsis in very low birth weight infants from singleton and multiple-gestation births

MRSA colonization and risk of infection in the neonatal and pediatric ICU: a meta-analysis

Relationship between maternal and neonatal Staphylococcus aureus colonization

Centers for Disease Control and Prevention: NICU: S. aureus Guidelines

Healthcare Infection Control Practices Advisory Committee, & HICPAC/SHEA/APIC/IDSA Hand Hygiene Task Force. Guideline for Hand Hygiene in Health-Care Settings. Recommendations of the Healthcare Infection Control Practices Advisory Committee and the HICPAC/SHEA/APIC/IDSA Hand Hygiene Task Force. Society for Healthcare Epidemiology of America/Association for Professionals in Infection Control/Infectious Diseases Society of America

Eliminating MRSA transmission in a tertiary neonatal unit-A quality improvement initiative

Evidence-based model for hand transmission during patient care and the role of improved practices

Methicillin-resistant Staphylococcus aureus in the neonatal intensive care unit

Active Surveillance Cultures and Decolonization to Reduce Staphylococcus aureus Infections in the Neonatal Intensive Care Unit

Role of decolonization in a comprehensive strategy to reduce methicillinresistant Staphylococcus aureus infections in the neonatal intensive care unit: an observational cohort study

Association of an Active Surveillance and Decolonization Program on Incidence of Clinical Cultures Growing Staphylococcus aureus in the Neonatal Intensive Care Unit

Effect of Treating Parents Colonized With Staphylococcus aureus on Transmission to Neonates in the Intensive Care Unit: A Randomized Clinical Trial

Mupirocin and Chlorhexidine Genotypic Resistance Found in Staphylococcus aureus Isolated From Young Infants Below 90 Days Old: A Genetic Basis for Eradication Failure

Mupirocin resistance related to increasing mupirocin use in clinical isolates of methicillin-resistant Staphylococcus aureus in a pediatric population

Invasive candidiasis in neonates and children

Risk factors for candidemia in Neonatal Intensive Care Unit patients. The National Epidemiology of Mycosis Survey study group

Neonatal candidiasis: diagnosis, prevention, and treatment

Risk factors for candidemia in critically ill infants: a matched casecontrol study

Fluconazole use and safety in the nursery

Clinical hepatotoxicity associated with antifungal agents

Fluconazole prophylaxis in extremely low birth weight infants: association with cholestasis

Fluconazole prophylaxis against fungal colonization and infection in preterm infants

Effect of fluconazole prophylaxis on candidiasis and mortality in premature infants: a randomized clinical trial

Randomised controlled trial of prophylactic fluconazole versus nystatin for the prevention of fungal colonisation and invasive fungal infection in very low birth weight infants

Prophylactic systemic antifungal agents to prevent mortality and morbidity in very low birth weight infants

Fungal Ecology in a Tertiary Neonatal Intensive Care Unit after 16 Years of Routine Fluconazole Prophylaxis: No Emergence of Native Fluconazole-Resistant Strains

International comparison of guidelines for managing neonates at the early phase of the SARS-CoV-2 pandemic

An Analysis of 38 Pregnant Women With COVID-19, Their Newborn Infants, and Maternal-Fetal Transmission of SARS-CoV-2: Maternal Coronavirus Infections and Pregnancy Outcomes

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)

Antibodies at Delivery in Women, Partners, and Newborns

Immune Response of Neonates Born to Mothers Infected With SARS-CoV-2

Transmission of SARS-CoV-2 through breast milk and breastfeeding: a living systematic review

Neonatal management and outcomes during the COVID-19 pandemic: an observation cohort study

American Academy of Pediatrics FAQs: Management of infants born to mothers with COVID-19

Preliminary Findings of mRNA Covid-19 Vaccine Safety in Pregnant Persons

Maternal and Child Outcomes Reported by Breastfeeding Women Following Messenger RNA

Vaccination